New Oral Medication Shows Promise for Type 2 Diabetes Management and Weight Reduction

Clinical trial results indicate that adding oral orforglipron to basal insulin therapy significantly improves glycemic control and reduces body weight in adults with type 2 diabetes. Data from the ACHIEVE-5 trial, presented at a major scientific session, showed these benefits without an increased risk of low blood sugar. These findings align with previous research on the medication.